References
- Araújo F, Gouvinhas C, Fontes F, La Vecchia C, Azevedo A, Lunet N. Trends in cardiovascular diseases and cancer mortality in 45 countries from five continents (1980-2010). Eur J Prev Cardiol. 2014;21(8):1004-17; DOI: 10.1177/2047487313497864.
- Liang Z, He Y, Hu X. Cardio-oncology: mechanisms, drug combinations, and reverse cardio-oncology. Int J Mol Sci. 2022: 23(18):10617; DOI: 10.3390/ijms231810617.
- Shi S, Lv J, Chai R, Xue W, Xu X, Zhang B, Li Y, Wu H, Song Q, Hu Y. Opportunities and challenges in cardio-oncology: a bibliometric analysis from 2010 to 2022. Curr Probl Cardiol. 2023;48(8):101227; DOI:10.1016/j. cpcardiol.2022.101227.
- Kappel C, Rushton M, Johnson C, Aseyev O, Small G, Law A, Ivars J, Dent SF. Clinical experience of patients referred to a multidisciplinary cardio-oncology clinic: an observational cohort study. Curr Oncol. 2019;26(3):e322-7; DOI:10.3747/co.26.4509.
- Burashnikov A, Abbate A, Booz GW. Cardiovascular complications of anticancer therapy: a developing storm in medicine. J Cardiovasc Pharmacol. 2022;80(4):491-2; DOI:10.1097/FJC.0000000000001355.
- Han X, Zhou Y, Liu W. Precision cardio-oncology: understanding the cardiotoxicity of cancer therapy. NPJ Precis Oncol. 2017;1(1):31; DOI:10.1038/s41698-017-0034-x.
- Lenneman CG, Sawyer DB. Cardio-oncology: an update on cardiotoxicity of cancer-related treatment. Circ Res. 2016;118(6):1008-20; DOI:10.1161/CIRCRESAHA.115.303633.
- Curigliano G, Cardinale D, Dent S, Criscitiello C, Aseyev O, Lenihan D, Cipolla CM. Cardiotoxicity of anticancer treatments: epidemiology, detection, and management. CA Cancer J Clin. 2016;66(4):309-25; DOI:10.3322/caac.21341.
- Manrique CR, Park M, Tiwari N, Plana JC, Garcia MJ. Diagnostic strategies for early recognition of cancer therapeutics–related cardiac dysfunction. Clin Med Insights Cardiol. 2017;11:1179546817697983; DOI:10.1177/1179546817697983.
- Ellahham S, Khalouf A, Elkhazendar M, Dababo N, Manla Y. An overview of radiation-induced heart disease. Radiat Oncol J. 2022;40(2):89-102; DOI:10.3857/roj.2021.00766.
- Asteggiano R, Aboyans V, Lee G, Salinger S, Richter D. Cardiology care deliverd to cancer patients. Eur Heart J. 2020;41(2):205-6; DOI:10.1093/eurheartj/ehz935.
- Bayles CE, Hale DE, Konieczny A, Anderson VD, Richardson CR, Brown KV, Nguyen JT, Hecht J, Schwartz N, Kharel MK, Amissah F, Dowling TC, Nybo SE. Upcycling the anthracyclines: New mechanisms of action, toxicology, and pharmacology. Toxicol Appl Pharmacol. 2023;459:116362; DOI:10.1016/j.taap.2022.116362.
- Beretta GL, Zunino F. Molecular mechanisms of anthracycline activity. Top Curr Chem. 2008;283:1-19; DOI:10.1007/128_2007_3.
- Volkova M, Raymond Russell I. Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment. Curr Cardiol Rev. 2011;7(4):214-20; DOI:10.2174/157340311799960645.
- Mohan N, Jiang J, Dokmanovic M, Wu WJ. Trastuzumab-mediated cardiotoxicity: current understanding, challenges, and frontiers. Antib Ther. 2018;1(1):13-7; DOI:10.1093/abt/tby003.
- Boekhout AH, Beijnen JH, Schellens JHM. Trastuzumab. Oncologist. 2011;16(6):800-10; DOI:10.1634/theoncologist.2010-0035.
- Vu T, Claret FX. Trastuzumab:updated mechanisms of action and resistance in breast cancer. Front Oncol. 2012;2:62; DOI:10.3389/fonc.2012.00062.
- Jawa Z, Perez RM, Garlie L, Singh M, Qamar R, Khandheria BK, Jahangir A, Shi Y. Risk factors of trastuzumab-induced cardiotoxicity in breast cancer: a meta-analysis. 2016;95(44):e5195; DOI:10.1097/MD.0000000000005195.
- Nicolazzi MA, Carnicelli A, Fuorlo M, Scaldaferri A, Masetti R, Landolfi R, Favuzzi AMR. Anthracycline and trastuzumab-induced cardiotoxicity in breast cancer. Eur Rev Med Pharmacol Sci. 2018;22(7):2175-85; DOI:10.26355/eurrev_201804_14752.
- Zhang N, Yin Y, Xu SJ, Chen WS. 5-Fluorouracil: mechanisms of resistance and reversal strategies. Molecules. 2008;13(8):1551-69; DOI:10.3390/molecules13081551.
- Sara JD, Kaur J, Khodadadi R, Rehman M, Lobo R, Chakrabarti S, et al. 5-fluorouracil and cardiotoxicity: a review. Ther Adv Med Oncol. 2018;10:1758835918780140; DOI:10.1177/1758835918780140.
- Christine M. Stork, Susan M. Schreffler. Cyclophosphamide. In: Wexler P, editor. Encyclopedia of toxicology, 4th ed. Science Direct: Academic Press; 2024. p. 417-421.
- Voelcker G. The real mechanism of action of cyclophosphamide and other oxazaphosphorine cytostatics. Japan J Res. 2020;1(2):1-2; DOI: 10.33425/2690-8077.1007.
- Winkelstein A. Mechanisms of immunosuppression: effects of cyclophosphamide on cellular immunity. Blood. 1973;41(2):273-84; DOI:10.1182/blood.V41.2.273.273.
- Madondo MT, Quinn M, Plebanski M. Low dose cyclophosphamide: mechanisms of T cell modulation. Cancer Treat Rev. 2016;42:3-9; DOI:10.1016/J.CTRV.2015.11.005.
- Kamel SS, Abdelbaky NA, Sayed-Ahmed MM, Karkeet RM, Osman AMM, Fouad MA. Cyclophosphamide-induced cardiotoxicity. Azhar Inter J Pharm Med Sci. 2022;2(2):1-8; DOI:10.21608/AIJPMS.2022.114213.1103.
- Rawat PS, Jaiswal A, Khurana A, Bhatti JS, Navik U. Doxorubicin-induced cardiotoxicity: an update on the molecular mechanism and novel therapeutic strategies for effective management. Biomed Pharmacother. 2021;139:111708; DOI:10.1016/j.biopha.2021.111708.
- Nabiałek-Trojanowska I, Lewicka E, Wrona A, Kaleta AM, Lewicka-Potocka Z, Raczak G, Dziadziuszko R. Cardiovascular complications after radiotherapy. Cardiol J. 2020;27(6):836-47; DOI:10.5603/CJ.a2018.0120.
- Pedersen LN, Schiffer W, Mitchell JD, Bergom C. Radiation-induced cardiac dysfunction: Practical implications. Kardiol Pol. 2022;80(3):256-65; DOI:10.33963/KP.a2022.0066.
- Nolan MT, Russell DJ, Marwick TH. Long-term risk of heart failure and myocardial dysfunction after thoracic radiotherapy: a systematic review. Can J Cardiol. 2016;32(7):908-20; DOI:10.1016/j.cjca.2015.12.020.
- Młot B, Rzepecki P. Kardiotoksyczność leczenia onkologicznego. Nowotwory J Oncol. 2010;60(6):536-547.
- Kucharska W, Negrusz-Kawecka M, Gromkowska M. Cardiotoxicity of oncological treatment in children. Adv Clin Exp Med. 2012;21(3):281-8.
- Zou B, Schuster JP, Niu K, Huang Q, Rühle A, Huber PE. Radiotherapy- induced heart disease: a review of the literature. Precis Clin Med. 2019;2(4):270-82; DOI:10.1093/pcmedi/pbz025.
- Geiger S, Lange V, Suhl P, Heinemann V, Stemmler HJ. Anticancer therapy induced cardiotoxicity: review of the literature. Anticancer Drugs. 2010;21(6):578-90; DOI:10.1097/CAD.0b013e3283394624.
- Minniti G, Goldsmith C, Brada M. Radiotherapy. Handb Clin Neurol. 2012;104:215-28; DOI:10.1016/B978-0-444-52138-5.00016-5.
- Gramatyka M. Cardiotoxicity as undesired side effect in the treatment of breast cancer. Postepy Hig Med Dosw. 2014;68:483-97; DOI:10.5604/17322693.1101581.
- Kuribayashi K, Finnberg N, Jeffers JR, Zambetti GP, El-Deiry WS. The relative contribution of pro-apoptotic p53-target genes in the triggering of apoptosis following DNA damage in vitro and in vivo. Cell Cycle. 2011;10(14):2380-9; DOI:10.4161/cc.10.14.16588.
- Filopei J, Frishman W. Radiation-induced heart disease. Cardiol Rev. 2012;20(4):184-8; DOI:10.1097/CRD.0b013e3182431c23.
- Przybyszewski WM, Wideł M, Rzeszowska-Wolny J. Kardiotoksyczne nastepstwa promieniowania jonizujacego i antracyklin. Postepy Hig Med Dosw. 2006;60:397-405.
- Merrifield M, Kovalchuk O. Epigenetics in radiation biology: a new research frontier. Front Genet. 2013;4(4):40; DOI:10.3389/fgene.2013.00040.
- Shim G, Ricoul M, Hempel WM, Azzam EI, Sabatier L. Crosstalk between telomere maintenance and radiation effects: a key player in the process of radiation-induced carcinogenesis. Mutat Res. 2014;760:1-17; DOI:10.1016/j.mrrev.2014.01.001.
- McKenna MJ, Bailey SM. Chromosomal and telomeric biomarkers of normal tissue injury to evaluate risk of degenerative health effects (secondary malignancy, cardiovascular disease) post radiation therapy. Transl Cancer Res. 2017;6(5):789-94; DOI:10.21037/tcr.2017.05.20.
- Coluzzi E, Leone S, Sgura A. Oxidative stress induces telomere dysfunction and senescence by replication fork arrest. Cells. 2019;8(1):19; DOI:10.3390/cells8010019.
- Luxton JJ, McKenna MJ, Taylor LE, George KA, Zwart SR, Crucian BE, Drel VR, Garrett-Bakelman FE, Mackay MJ, Butler D, Foox J, Grigorev K, Bezdan D, Meydan C, Smith SM, Sharma K, Mason CE, Bailey SM. Temporal telomere and DNA damage responses in the space radiation environment. Cell Rep. 2020;33(10):108435; DOI:10.1016/j.celrep.2020.108435.
- M’kacher R, Girinsky T, Colicchio B, Ricoul M, Dieterlen A, Jeandidier E, Heidingsfelder L, Cuceu C, Shim G, Frenzel M, Lenain A, Morat L, Bourhis J, Hempel WM, Koscielny S, Paul JF, Carde P, Sabatier L. Telomere shortening: a new prognostic factor for cardiovascular disease post-radiation exposure. Radiat Prot Dosimetry. 2015;164(1-2):134-7; DOI:10.1093/rpd/ncu296.
- Bovelli D, Plataniotis G, Roila F. Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO clinical practice guidelines. Ann Oncol. 2010;21(5): v277-82; DOI:10.1093/annonc/mdq200.
- López-Sendón J, Álvarez-Ortega C, Zamora Auñon P, Buño Soto A, Lyon AR, Farmakis D, Cardinale D, Canales Albendea M, Feliu Batlle J, Rodríguez Rodríguez I, Rodríguez Fraga O, Albaladejo A, Mediavilla G, González-Juanatey JR, Martínez Monzonis A, Gómez Prieto P, González-Costello J, Serrano, Antolín JM, Cadenas Chamorro R, López Fernández T. Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry. Eur Heart J. 2020;41(18):1720-9; DOI:10.1093/eurheartj/ehaa006.
- Dong J, Chen H. Cardiotoxicity of anticancer therapeutics. Front Cardiovasc Med. 2018;5(9); DOI:10.3389/fcvm.2018.00009.
- Curigliano G, Cardinale D, Suter T, Plataniotis G, De azambuja E, Sandri MT, Criscitiello C, Goldhirsch A, Cipolla C, Roila F. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO clinical practice guidelines. Ann Oncol. 2012;23(7):vii155-66; DOI:10.1093/annonc/mds293.
- Korzeniowska K, Cieślewicz A, Jankowski J, Neumann D, Jabłecka. Powikłania sercowo-naczyniowe leczenia onkologicznego. Farmac Wspol. 2016;9:189-93;
- Menna P, Salvatorelli E. Primary prevention strategies for anthracycline cardiotoxicity: a brief overview. Chemotherapy. 2017;62(3):159-68; DOI:10.1159/000455823.
- Kong CY, Guo Z, Song P, Zhang X, Yuan YP, Teng T, Yan L, Tang QZ. Underlying the mechanisms of doxorubicin-induced acute cardiotoxicity: oxidative stress and cell death. Int J Biol Sci. 2022;18(2):760-70; DOI:10.7150/ijbs.65258.
- Tajiri K, Aonuma K, Sekine I. Cardiovascular toxic effects of targeted cancer therapy. Jap J Clin Oncol. 2017;47(9):779-85; DOI:10.1093/jjco/hyx071.
- Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggiano R, Galderisi M, Habib G, Lenihan DJ, Lip GYH, Lyon AR, Lopez Fernandez T, Mohty D, Piepoli MF, Tamargo J, Torbicki A, Suter TM, ESC Scientific Document Group. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(36):2768-801; DOI:10.1093/eurheartj/ehw211.
- Georgiyeva K, Blake P. Medical sciences – cardiovascular side effects of colon cancer therapy. Sci Eur. 2022;99:20-4; DOI:10.5281/zenodo.7014308.
- Bikiewicz A, Banach M, von Haehling S, Maciejewski M, Bielecka-Dabrowa A. Adjuvant breast cancer treatments cardiotoxicity and modern methods of detection and prevention of cardiac complications. ESC Heart Fail. 2021;8(4):2397-418 DOI:10.1002/ehf2.13365.
- Alexandre J, Cautela J, Ederhy S, Damaj GL, Salem JE, Barlesi F, Farnault L, Charbonnier A, Mirabel M, Champiat S, Cohen-Solal A, Cohen A, Dolladille C, Thuny F. Cardiovascular toxicity related to cancer treatment: a pragmatic approach to the american and european cardio-oncology guidelines. J Am Heart Assoc. 2020;9(18); DOI:10.1161/JAHA.120.018403.
- Thuny F, Alexandre J, Salem JE, Mirabel M, Dolladille C, Cohen-Solal A, Cohen A, Ederhy S, Cautela J. Management of immune checkpoint inhibitor- induced myocarditis: the French Working Group’s Plea for a pragmatic approach. JACC CardioOncol. 2021;3(1):157-61; DOI:10.1016/j. jaccao.2020.12.001.
- Ananthan K, Lyon AR. The role of biomarkers in cardio-oncology. J Cardiovasc Transl Res. 2020;13(3):431-50; DOI:10.1007/s12265-020-10042-3.
- Beyer AM, Bonini MG, Moslehi J. Cancer therapy-induced cardiovascular toxicity: old/new problems and old drugs. Am J Physiol Heart Circ Physiol. 2019;317:164-7; DOI:10.1152/ajpheart.00277.2019.
- Guo J, Fang P, Shi W, Luo P, Huo S, Yan D, Wang M, Peng D, Men L, Li S, Lv J, Lin L. Preexisting cardiovascular risk factors and coronary artery atherosclerosis in patients with and without cancer. Cardiol Res Pract. 2022;2022:4570926; DOI: 10.1155/2022/4570926.
- Mamas MA, Matetic A. How common is pre-existing cardiovascular disease in cancer patients: what do we know? Does it matter? JACC Cardio- Oncol. 2022;4(2):254-7; DOI:10.1016/j.jaccao.2022.05.001.
- Batra A, Sheka D, Kong S, Cheung WY. Impact of pre-existing cardiovascular disease on treatment patterns and survival outcomes in patients with lung cancer. BMC Cancer. 2020;20(1):1004; DOI:10.1186/s12885-020-07487-9.
- Salz T, Zabor EC, Brown P de N, Dalton SO, Raghunathan NJ, Matasar MJ, Steingart R, Vickers AJ, Munksgaard PS, Oeffinger KC, Johanses C. Preexisting cardiovascular risk and subsequent heart failure among non-hodgkin lymphoma survivors. J Clin Oncol. 2017;35(34):3837-43; DOI: 10.1200/JCO.2017.72.4211.